Terns Pharmaceuticals to Participate in Upcoming November Investor Conferences
FOSTER CITY, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage...
Month: November 2023
Mainz Biomed Partners with Liquid Biosciences to Harness the Power of Artificial Intelligence (AI) to Develop Next-generation Colorectal Screening Test
Collaboration to utilize cutting-edge AI analysis platform for clinical trials and cancer screening test processingBERKELEY, Calif. and MAINZ, Germany, Nov....
Recursion Announces Data Collaboration Deal with Tempus, Top 50 Supercomputer Ambition Powered by NVIDIA, and Updated Focus of Collaboration with Bayer to Precision Oncology
With additional patient-centric data, compute power, and an exciting new focus for its Bayer collaboration, the company is accelerating the...
Recludix Pharma to Present at Two Investor Conferences in November
SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging...
PETVIVO HOLDINGS, INC. TO ANNOUNCE RESULTS FOR THE SECOND QUARTER ENDED SEPTEMBER 30, 2023
MINNEAPOLIS, MN, US, Nov. 09, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV and PETVW), an emerging biomedical device...
Vera Therapeutics Provides Business Update and Reports Third Quarter Financial Results
Phase 2b open-label extension eGFR and proteinuria data expected in the first quarter of 2024; actively adding sites and enrolling...
Immutep Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA® in First Line Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma
Media Release A total of 171 head and neck squamous cell carcinoma (HNSCC) patients enrolled in randomised, multicentre Phase IIb...
Spectral Medical Announces Third Quarter Results and Provides Corporate Update
Tigris Trial Enrollment Reaches 76 PatientsCrude mortality results continue to exceed expectations TORONTO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Spectral...
Landos Biopharma Provides Company Update and Reports Third Quarter 2023 Results
NEXUS Phase 2 Clinical Trial of NX-13 for Ulcerative Colitis Remains On Track with Top-line Results Planned for Q4 2024 Sufficient...
BioSig Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Westport, CT, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Westport, CT, Nov. 9, 2023 -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig”...
PDS Biotech Announces Updated Survival Data from NCI-Led Phase 2 Clinical Trial of PDS0101-Based Triple Combination Therapy in Advanced HPV16-Positive Cancer Patients which Show 75% Survival of ICI Naïve Patients at 36 Months
75% of immune checkpoint inhibitor (ICI) naïve patients remain alive at 36 months; published median overall survival (OS) in similar...
IBEX Reports Results for the Year Ended July 31, 2023
MONTRÉAL, Nov. 09, 2023 (GLOBE NEWSWIRE) -- IBEX Technologies Inc. (“IBEX” or the “Company”) (TSX Venture: IBT) today reported its...
Cocrystal Pharma to Discuss Progress with Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast
BOTHELL, Wash., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), announces that President...
Recce Pharmaceuticals Completes Dosing First Subjects at 15-Minute Infusion Rate in a Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsis
Phase I/II study is tracking to meet primary endpointsRECCE® 327 at 3,000mg over 15 minutes marks the fastest infusion rate...
Daré Bioscience Reports Third Quarter 2023 Financial Results and Provides Company Update
Conference Call and Webcast Today at 4:30 p.m. ET What to Expect for the Remainder of 2023 XACIATO™: receipt of...
Fulcrum Therapeutics to Participate at Upcoming November Investor Conferences
CAMBRIDGE, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing...
Avalyn Presents Data from its AP01 and AP02 Inhaled Therapeutics Programs for Pulmonary Fibrosis
Preclinical data that supported initiation of the completed Phase 1a AP02 inhaled nintedanib study to be presented for the first...
Candel Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
Initial survival data from phase 2 clinical trial of CAN-2409 in advanced non-small cell lung cancer (NSCLC) showed survival supportive...
Solid Biosciences to Participate at Jefferies London Healthcare Conference
CHARLESTOWN, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines...
Comera Life Sciences Reports Financial Results for Third Quarter 2023 and Recent Business Highlights
– Final stage of technical evaluation near completion in Comera’s research collaboration with Regeneron, a leading U.S. biotechnology company –...